Neil Mehta, M.D.
- Associate Professor of Medicine General Hepatology and Liver Transplantation Department of Medicine
Contact Information
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Education
Johns Hopkins University, BA, Neuroscience, 1998-2002
University of California, San Francisco School of Medicine, MD, 2002-2006
Residencies
- Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
- Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009
Fellowships
- University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
- University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013
Clinical Expertise
- Alcoholic Liver Disease
- Autoimmune Hepatitis
- Cirrhosis
- Drug-Induced Hepatitis
- Fulminant Hepatic Failure
- Hemochromatosis
- Hepatitis B
- Hepatitis C
- Hepatocellular Carcinoma (Liver Cancer)
- Liver Transplantation
- Living Donor Liver Transplantation
- Nonalcoholic Fatty Liver Disease
- Polycystic Liver Disease
- Primary Biliary Cirrhosis
- Primary Sclerosing Cholangitis
Biography
Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.
After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.
Research Overview
Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:
- Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
- Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.
Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.
Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.
Clinical Trials
- Study ID: NCT06084234Start Date: Jan 2024Estimated Completion Date: Dec 2034Condition(s): Liver Cancer, Cirrhosis, Hepatitis B, Hepatocellular Cancer
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 174
- Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023 Sep 07. View in PubMed
- Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant. Liver Transpl. 2023 Aug 29. View in PubMed
- Wang M, Cedars MI, Mehta N, Sarkar M. How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box. Am J Gastroenterol. 2023 Oct 02. View in PubMed
- Yilma M, Mehta N. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024 Jan; 33(1):133-142. View in PubMed
- Ivanics T, Claasen MP, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Quintini C, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Living Donor Liver Transplantation (LDLT) for Hepatocellular Carcinoma (HCC) within and Outside Traditional Selection Criteria: A Multicentric North American Experience. Ann Surg. 2023 Jul 31. View in PubMed
- View All Publications
In the News
- UCSF General Surgery Residency Program - - December 16, 2020Mignote Yilma, M.D., a general surgery resident, was accepted into the National Clinician Scholars Program (NCSP) at UCSF, starting in the 2021-22 academic year. The NCSP is a prestigious two-year post-doctoral fellowship that trains scholars in community-partnered research, implementation and dissemination sciences, and health system transformation. The goal of the program is to train healthcare leaders to work in diverse settings and cultivate health equity. As one of five NCSP Scholars, Dr. [...]
- UCSF Transplant Surgery - December 10, 2014Successful downstaging of selected patients with HCC (hepatocellular carcinoma) before liver transplantation leads to excellent 5-year recurrence-free and overall survival rates post-transplant, according to a just-reported multicenter study led by UCSF Transplant Program investigators. Medscape Medical News reported on these results at the Liver Meeting 2014: American Association for the Study of Liver Diseases (AASLD) where the UCSF study findings were presented: Treating lesions with [...]